Alkahest is developing treatments for neurodegenerative and age-related diseases. Many proteins that increase or decrease with age can be identified in the blood plasma. Alkahest is characterizing these proteins, known as chronokines, to create therapeutics to slow down or reverse age-related diseases. In particular, Alkahest is interested in chronokines involved in promoting restorative biological processes or pathological degenerative processes as therapeutic targets. Target identification follows the traditional pharmaceutical method, supplemented with Alkahest’s highly selected and refined plasma fractions. Using this approach, Alkahest has many product candidates in Phase 1 & 2 clinical trials.